InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has commented on a recent study that indicated that cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2. The comments came from lead research scientist Dr. Richard van Breeman, who granted an interview with vice.com discussing the independent study. In his comments, Breemen […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
January 14, 2022
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator of drug delivery platforms, is increasing the effectiveness of orally administered drugs. With oral absorption being the most convenient and widely used route for taking medications, decades of research have advanced the understanding of critical factors controlling oral bioavailability. Scientists are now better understanding the physiological function […]
After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements
Lexaria has multiple studies planned that will commence early in 2022 DehydraTECH increases Lexaria’s ability to leverage multiple markets, including the growing CBD sector, which is expected to meet and exceed $108 billion in revenue by 2027 DehydraTECH can increase the efficacy of the drugs being administered, offering faster absorption and lowering the delivery time […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022
January 12, 2022
Lexaria Bioscience’s ongoing human clinical studies for its patented and trademarked DehydraTECH technology have yielded progressively optimistic results in 2021 regarding DehydraTECH’s ability to provide effective solutions for the cardiovascular industry DehydraTECH is being studied for its capacity to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Independent Review Board Approval for Its Most Ambitious, Comprehensive Human Study Yet
January 10, 2022
Lexaria has received approval from the Independent Review Board for its DehydraTECH-CBD Human Clinical HYPER-H21-4 study The approval signals the company has taken the appropriate steps to protect the rights and welfare of human subjects participating in its fourth human study HYPER-H21-4 should “de-risk” outcomes prior to Lexaria’s planned entry into regulatory pathways for the […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)
January 6, 2022
The strategic move to incorporate SRAX is designed to bring investor visibility for all of the upcoming events that Lexaria has planned for 2022 Lexaria’s patented DehydraTECH(TM) technology is poised to leverage multiple industries – notably the CBD industry, with a projected value of $108.8 billion by 2027 The advertising and media contract will allow […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time
January 4, 2022
As a significant number of drugs fail to reach the market owing to poor bioavailability, Lexaria Bioscience Corp. (NASDAQ: LEXX) is among those companies exploring different tools and methods to try to solve the problem. Lexaria is currently leading the industry in terms of innovation in drug delivery platforms. “Its patented DehydraTECH(TM) technology is specifically […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study
December 29, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-CBD human hypertension study HYPER-H21-4; the approval was received earlier than anticipated. The study is designed to “de-risk” outcomes prior to the company’s planned entry into regulatory pathways for the use of DehydraTECH-CBD to treat […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expects Study Results to Show its Patented Tech’s Value in Treating Hypertension Patients
December 27, 2021
Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating hypertension (high blood pressure) The company has completed multiple studies of the benefits of DehydraTECH(TM), in combination with cannabidiol to combat hypertension conditions and consequentially benefit cardiovascular patients Lexaria recently […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD
December 22, 2021
In a recent human clinical trial, HYPER-H21-2, DehydraTECH™-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat cardiovascular and other diseases beyond hypertension Lexaria’s patented technology DehydraTECH improves how APIs enter the bloodstream –making multiple benefits possible such as increased delivery speed, increase in brain absorbency, higher bioavailability, and lower costs The company has […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
December 21, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) is embarking on new programs as well as extending ongoing ones as it pursues regulatory approvals and entry into different market sectors. In January 2022, the company expects to report blood pressure findings from its third human hypertension study, HYPER-H21-3, building on the successes of the first two human studies […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)
December 17, 2021
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced its entry into an advertising and media agreement for media buys and digital marketing with SRAX (NASDAQ: SRAX). Under the agreement, SRAX will act as the agent for Lexaria and will engage and manage media companies to create advertising materials and […]
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension
Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood pressure) The company’s studies earlier this year indicated the potential of DehydraTECH to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability […]
InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
December 14, 2021
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week. The study, undertaken to examine the effects of DehydraTECH-CBD upon acute pulmonary hypertension, used a blinded design with administration of a single 300mg dose […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical hypertension study HYPER-H21-4, its most ambitious one yet Lexaria plans to sublicense its patented DehydraTECH(TM) technology worldwide, allowing for more people to benefit from it Going into 2022, the company […]
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion
December 10, 2021
Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s patented DehydraTECH(TM) to improve drug delivery processes for multiple indications Research will continue into the use of DehydraTECH-CBD for high blood pressure, as well as the technology’s potential for oral […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
December 8, 2021
Around 40% of available marketed drugs are poorly bioavailable or soluble, and about 90% of New Chemical Entities are known for their low solubility and permeability Lexaria’s patented DehydraTECH(TM) technology offers a solution by improving how APIs (active pharmaceutical ingredients) enter the bloodstream DehydraTECH achieves this by bypassing first-pass-liver metabolism By doing so, Lexaria is […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional results from its human clinical study HYPER-H21-2. The study was designed to evaluate the company’s proprietary DehydraTECH(TM)-processed cannabidiol (“CBD”) and its effectiveness in the treatment of hypertension. Results confirm the substance’s ability to reduce arterial stiffness and indicate potential broader applications beyond […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
December 7, 2021
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve delivery of lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”) into the bloodstream while speeding onset, increasing bioavailability and improving efficacy. DehydraTECH’s ability to enhance delivery promotes healthier oral ingestion methods and increased […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that it is participating in the Benzinga Global Small Cap Conference. The premier two-day virtual event is scheduled for Dec. 8–9, 2021. The company encourages shareholders and other interested parties to attend the event and learn more about investment opportunities within the global […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
December 2, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, […]
InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
November 24, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursues regulatory approval for DehydraTECH-CBD for potential use as a treatment for hypertension HYPER-H21-4 will build on successes witnessed in initial human hypertension studies The company, which has a fully funded R&D budget, recently announced new R&D programs covering multiple conditions, […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
November 18, 2021
Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds on findings from 2021 studies which supported significant advances in the oral nicotine, heart disease, and antiviral markets The 2022 program will continue to focus on the company’s patented DehydraTECH drug delivery […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4
November 12, 2021
Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and it’s most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings, as well as the HYPER-H21-3 study that is set to begin dosing in mid-November 2021 Lexaria’s goal is to pursue regulatory approval for its proprietary DehydraTECH-CBD for potential use […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
November 10, 2021
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of Lexaria’s 2022 work programs. “Calendar 2022 will continue to see significant milestones in utilizing […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio
November 3, 2021
Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition, the company provided updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease. “HYPER-H21-4 is the most ambitious study Lexaria has […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
November 1, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1,designed to evaluate whether its DehydraTECH(TM)-CBD (“CBD”) indicates superior ability to reduce seizure activity compared to both generic cannabidiol and Epidiolex. Epidiolex is the only CBD medication approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
October 29, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) was recently part of coverage by Zacks Small-Cap Research analysts based on its market potential. Zacks, which focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators, valued the company at […]
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Addresses the Needs of Medical THC Users
October 26, 2021
Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver the same THC levels than concentration-matched controls Lexaria believes that through DehydraTECH, it is meeting the needs of medical THC users with its rapid delivery, increased overall THC delivery and high […]
New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping
October 22, 2021
Oral drug delivery innovator Lexaria Bioscience is focused on providing alternatives to smoked or inhaled tobacco and cannabis products to help consumers reduce the threat to their lungs Lexaria’s patented technology — DehydraTECH(TM) — is a solution that processes active pharmaceutical ingredients into a powder or liquid form that can then be ingested with less […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Reveals Effectiveness of Proprietary Drug-Development Tech
October 20, 2021
Lexaria Bioscience (NASDAQ: LEXX), developers of the revolutionary DehydraTECH(TM) drug-delivery technology, has released study results focused on THC-A21-1, a THC oral format. According to the announcement, the study showed that Lexaria’s DehydraTECH THC solution delivers THC levels to blood plasma an estimated three times faster than standard MCT-based THC. Based on study results, it took only […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to Revolutionizing the Nicotine Industry with its Alternative Nicotine Delivery
Lexaria’s recent animal study on its patented DehydraTECH(TM) technology on nicotine absorption yielded ground-breaking results This study builds on an earlier 2018 study that demonstrated effective delivery of nicotine to the central nervous system in a rodent study The study’s success will serve as the foundation for a human trial that will compare the DehydraTECH-nicotine […]
InvestorNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Impacting the Pharmaceutical Industry
October 19, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to enhancing the speed and overall efficiency of orally delivered fat-soluble active molecules. The company is leveraging its drug delivery technology, DehydraTECH(TM), in the development of hypertension and anti-viral treatments — a big achievement already making an impact in the pharmaceutical industry. “Since Lexaria began working on […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Impressive Findings of Oral THC Absorption Study
October 13, 2021
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its recent oral tetrahydrocannabinol (“THC”) absorption study THC-A21-1 revealed that DehydraTECH(TM)-THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls. According to the update, […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in ‘Stock2Me’ Podcast
October 12, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in the latest episode of the “Stock2Me Podcast,” an IBN (InvestorBrandNetwork) solution to provide specialized content distribution via widespread syndication channels. Lexaria’s CEO and Chairman Chris Bunka joined the latest episode to discuss the company’s business model, his professional background […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Outcome of NIC-A21-1 Study Using DehydraTECH(TM)-Nicotine Pouches
October 8, 2021
The company believes that the study findings support its patented DehydraTECH(TM) system as being the world’s fastest-acting nicotine through oral absorption and a safer nicotine alternative for the 1.1 billion smokers of the world Plans for a human trial are in the design process, and Lexaria intends to use existing capital to execute the study […]
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Outstanding Results of Oral Nicotine Study
October 5, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECH(TM)-nicotine delivered via the oral pouch product format required only two to four minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched […]
Lexaria Bioscience Corp. (NASDAQ: LEXX) Oral Drug Use Technology Nets Zacks Research Coverage
Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs Lexaria is […]